Covidien, BioSynthema in nuclear medicine pact
This article was originally published in Clinica
Executive Summary
In a move to further expand its nuclear medicine portfolio, Covidien has forged an alliance with drug discovery company BioSynthema to develop and commercialise a radionuclide therapy for neuroendocrine cancer patients.